Biogen (BIIB) Stock Forecast & Price Target

Biogen
Bull Case

Here are some ways that investors could benefit from investing in Biogen Inc.:

• Biogen Inc. recently achieved a new 52-week high, with the stock trading at $226.36 as of September 24, 2026, reflecting strong market confidence and a significant upward trend from its 52-week low of $135.39.
• The company demonstrated strong financial performance in its most recent quarter, reporting earnings per share of $3.60, which significantly exceeded the analyst consensus estimate of $2.94, while also generating revenue of $2.74 billion, surpassing expectations of $2.46 billion.
• Biogen Inc. has secured Japanese approval for the at-home LEQEMBI Pen subcutaneous formulation for early Alzheimer’s disease, a development that enhances patient accessibility and potentially broadens the treatment reach for this critical neurological condition.
• Recent Phase 3 VALIANT study data published in the Clinical Journal of the American Society of Nephrology showed that EMPAVELI achieved a 75% relative reduction in proteinuria in adolescents with C3G or primary IC-MPGN, supporting a recent FDA label expansion that increases the drug's marketable value and therapeutic potential.
• Analyst sentiment remains positive, with a consensus rating of "Moderate Buy" and a consensus price target of $230.14, indicating that financial experts believe the stock has further upside potential relative to its current trading price.